USE OF DAA IN PATIENTS WITH HCV-ASSOCIATED LIVER DAMAGE

dc.contributor.author	Bakhronov Jakhongir Jasurovich
dc.date.accessioned	2025-12-29T18:01:09Z
dc.date.issued	2025-12-17
dc.description.abstract	190 patients were observed, including 135 with a diagnosis of chronic hepatitis C (CHC) and 55 with a diagnosis of viral liver cirrhosis. Of these, 103 patients had genotype 1b, 48 had genotype 1a, 16 had genotype 3a, 10 had genotype 3a/b, and 13 had genotype 2. All patients underwent quantitative HCV viral load determination using PCR. The level of liver fibrosis was also determined using a non-invasive method called fibroscan. Patients were prescribed direct-acting antiviral drugs (DAA) for antiviral therapy.
dc.format	application/pdf
dc.identifier.uri	https://webofjournals.com/index.php/5/article/view/5650
dc.identifier.uri	https://asianeducationindex.com/handle/123456789/25043
dc.language.iso	eng
dc.publisher	Web of Journals Publishing
dc.relation	https://webofjournals.com/index.php/5/article/view/5650/5670
dc.rights	https://creativecommons.org/licenses/by-nc-nd/4.0
dc.source	Web of Medicine: Journal of Medicine, Practice and Nursing ; Vol. 3 No. 12 (2025): WOM; 201-206
dc.source	2938-3765
dc.subject	Chronic hepatitis C, liver cirrhosis, direct-acting antiviral drugs, fibroscan.
dc.title	USE OF DAA IN PATIENTS WITH HCV-ASSOCIATED LIVER DAMAGE
dc.type	info:eu-repo/semantics/article
dc.type	info:eu-repo/semantics/publishedVersion
dc.type	Peer-reviewed Article

item.page.files

pagination.showing.labelpagination.showing.detail

item.page.filesection.name: jasurovich_2025_use_of_daa_in_patients_with_hcv-associat.pdf
item.page.filesection.size: 348.1 KB
item.page.filesection.format: Adobe Portable Document Format